Hansa Biopharma — August 2022
-
European Society for Organ Transplantation’s (ESOT) guidelines for desensitization treatment of highly sensitized kidney transplant patients published in Transplant International
-
Hansa Biopharma: Fireside chat Soren Tulstrup, CEO with analyst Ed Nash at Canaccord Annual Growth Conference
-
-
Test
-
-
Hansa Biopharma and Medison Pharma announce positive reimbursement decision in Poland for Idefirix
in highly sensitized kidney transplant patients -
-
Typisk at kursen siver når der er uro og negative markeder….tror shorterne udnytter nervøsiteten hver gang der er uro.
desværre -
Ja, det er lidt ærgerligt at se på. Men casen er jo kun forbedret, så det må jo skyldes generel nervøsitet, hovedsageligt. På den anden side hvis basecase er kurs 450.. så er det jo lidt ligegyldigt, om den ligger på 60 eller 80 lige nu.. det handler vel så mest om dit eget GAK vs basecase. Og det er jo det samme nu som før.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind